The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.5M data for 728K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

22 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Discovery of furan carboxylate derivatives as novel inhibitors of ATP-citrate lyase via virtual high-throughput screening.EBI
Harvard Medical School
Design and synthesis of emodin derivatives as novel inhibitors of ATP-citrate lyase.EBI
Harvard Medical School
The lipogenesis pathway as a cancer target.EBI
Wayne State University
The biology and chemistry of hyperlipidemia.EBI
Sinhgad College of Pharmacy
ATP-citrate lyase as a target for hypolipidemic intervention. Sulfoximine and 3-hydroxy-beta-lactam containing analogues of citric acid as potential tight-binding inhibitors.EBI
Smithkline Beecham Pharmaceuticals
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.EBI
University of Cambridge
NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family.EBI
Johann Wolfgang Goethe University
Macrocyclization strategy for improving candidate profiles in medicinal chemistry.EBI
Gachon University
2-hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors.EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
Opportunities and Challenges for Inhibitors Targeting Citrate Transport and Metabolism in Drug Discovery.EBI
China Pharmaceutical University
Structurally Diverse Triterpene-26-oic Acids as Potential Dual ACL and ACC1 Inhibitors from the Vulnerable Conifer EBI
Fudan University
Forrestiacids E-K: Further [4 + 2]-Type Triterpene-Diterpene Hybrids as Potential ACL Inhibitors from the Vulnerable Conifer EBI
Taizhou University
Cinerols, Nitrogenous Meroterpenoids from the Marine Sponge EBI
Shanghai Jiao Tong University
ATP-Citrate lyase as a target for hypolipidemic intervention. 2. Synthesis and evaluation of (3R,5S)-omega-substituted-3-carboxy-3, 5-dihydroxyalkanoic acids and their gamma-lactone prodrugs as inhibitors of the enzyme in vitro and in vivo.EBI
Smithkline Beecham Pharmaceuticals
ATP-citrate lyase as a target for hypolipidemic intervention. Design and synthesis of 2-substituted butanedioic acids as novel, potent inhibitors of the enzyme.EBI
Smithkline Beecham Pharmaceuticals
Synthesis of novel thiol-containing citric acid analogues. Kinetic evaluation of these and other potential active-site-directed and mechanism-based inhibitors of ATP citrate lyase.EBI
Smithkline Beecham Pharmaceuticals
ATP citrate lyase (ACLY) inhibitors: An anti-cancer strategy at the crossroads of glucose and lipid metabolism.EBI
University of Pisa
Synthesis and hypolipidemic and antidiabetogenic activities of beta,beta,beta',beta'-tetrasubstituted, long-chain dioic acids.EBI
Hebrew University
Compound as protein kinase inhibitor, and pharmaceutical composition comprising thereofBDB
Hk Inno.N
NUCLEAR TRANSPORT MODULATORS AND USES THEREOFBDB
Karyopharm Therapeutics
OX2R compoundsBDB
University of Texas System